Interestingly, transforming growth factor (TGF)-β is a well-known contributor to EMT, and TGF-β downstream signaling was found to be highly active in high-grade glioblastomas, the most fatal tumor of the central nervous system, where elevated TGF-β activity was associated with poor clinical outcome [4]. This evidence concerns the gene TGFB1 and central nervous system cancer.